抗原嵌合受体T细胞(CAR-T)在非小细胞肺癌中的应用  

Application of Chimeric Antigen Receptor-T Cell (CAR-T) in Non-Small Cell Lung Cancer

作　　者：遆嬿羽 兀威[2] 杨淑梅[3] 李岚 田智杰 康文玥 

机构地区：[1]西安医学院,陕西 西安 [2]西安医学院第二附属医院呼吸与危重症医学科,陕西 西安 [3]陕西省人民医院呼吸与危重症医学科,陕西 西安 [4]陕西省人民医院血液内科,陕西 西安

出　　处：《临床医学进展》2021年第10期4373-4377,共5页Advances in Clinical Medicine

摘　　要：肺癌是世界上最常见和最致命的癌症之一,其主要有两种类型,小细胞肺癌和非小细胞肺癌,而非小细胞肺癌约占所有确诊肺癌的85%,在肺癌死亡人数中具有较大的占比,近年来,开发基因工程T细胞在基础和临床癌症研究中取得了重大进展,作为免疫治疗的新型药物,抗原嵌合受体T细胞(Chimeric antigen receptor-T cell, CAR-T)在非小细胞肺癌中显示出巨大的前景。本文就CAR-T细胞疗法在非小细胞肺癌中的应用作一综述。Lung cancer is one of the most common and fatal cancers in the world. There are two main types of lung cancer, small-cell carcinoma and non-small-cell lung carcinoma, and non-small-cell lung carcinoma accounts for about 85% of all diagnosed lung cancer and a large proportion of lung cancer deaths. In recent years, the development of genetically engineered T cells has made significant progress in basic and clinical cancer research as a new drug for immunotherapy. The chimeric antigen receptor-T cell (CAR-T cell) has shown great promise in non-small-cell lung carcinoma. This article reviews the application of CAR-T cell therapy in non-small-cell lung carcinoma.

关 键 词：非小细胞肺癌 CAR-T 应用 

分 类 号：R73[医药卫生—肿瘤]